- Home
- CYRX vs FTH Comparison
CYRX vs FTH Comparison
Compare CYRX & FTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYRX | FTH |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 814.9M | 835.7M |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CYRX | FTH |
|---|---|---|
| Price | $16.84 | $34.64 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $13.31 | N/A |
| AVG Volume (30 Days) | ★ 440.9K | 293.0K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $176,177,000.00 | N/A |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $8.45 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.61 | $17.50 |
| 52 Week High | $17.20 | $42.14 |
Technical Indicators
Market Signals| Indicator | CYRX | FTH |
|---|---|---|
| Relative Strength Index (RSI) | 61.56 | 50.77 |
| Support Level | $14.55 | $30.30 |
| Resistance Level | $16.87 | $36.63 |
| Average True Range (ATR) | 0.55 | 3.49 |
| MACD | 0.10 | -0.58 |
| Stochastic Oscillator | 86.56 | 29.44 |
Price Performance
Historical ComparisonAbout CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
About FTH Faeth Therapeutics Inc. Common Stock
Faeth Therapeutics Inc is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The company's principal program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer.